This website is intended for UK healthcare professionals only Log in | Register

Tag Archives: cardiovascular safety

Drugs for diabetes: part 6 GLP-1 receptor agonists

August 2011 Br J Cardiol 2011;18:167–69

Drugs for diabetes: part 6 GLP-1 receptor agonists

Claire McDougall, Gerard A McKay, Miles Fisher

Abstract

(more…)

| Full text
Drugs for diabetes: part 5 DPP-4 inhibitors

June 2011 Br J Cardiol 2011;18:130–2

Drugs for diabetes: part 5 DPP-4 inhibitors

Claire McDougall, Gerard A McKay, Miles Fisher

Abstract

Introduction Type 2 diabetes, which is increasing in prevalence, is a major risk factor for cardiovascular morbidity and mortality. Although there are a number of pharmacological approaches to the management of type 2 diabetes, a large number of patients fail to reach glycaemic targets and a limited amount of drugs have shown benefit without glycaemic control. Therefore, there is still an unmet need in this therapeutic area. One recent advance in the management of type 2 diabetes has been the development and clinical use of dipeptidyl peptidase-4 (DPP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists.1 The development of the

| Full text
Drugs for diabetes: part 3 thiazolidinediones

February 2011 Br J Cardiol 2011;18:24-7

Drugs for diabetes: part 3 thiazolidinediones

David McGrane, Miles Fisher, Gerard A McKay

Abstract

Introduction During the past 10 to 15 years, numerous drugs have been introduced for the treatment of patients with type 2 diabetes to prevent the complications of poor glycaemic control. Two such oral drugs, rosiglitazone and pioglitazone, belong to the class of drugs called thiazolidinediones (TZDs), also known as glitazones. Both were licensed for use as monotherapy or in combination with other hypoglycaemic drugs. Through their actions on peroxisome proliferator-activated receptor (PPARγ), they improve hyperglycaemia and alter dyslipidaemia. It was hoped this would translate into cardiovascular benefits for patients taking them. Recent e

| Full text

March 2003 Br J Cardiol 2003;10:137-40

Sibutramine: a safety profile

Omar Ali

Abstract

No content available

| Full text
Close

You are not logged in

You need to be a member to print this page.
Find out more about our membership benefits

Register Now Already a member? Login now
Close

You are not logged in

You need to be a member to download PDF's.
Find out more about our membership benefits

Register Now Already a member? Login now